Overview BIOPIA

The introduction of biologics and biopharmaceuticals

  • Have revolutionised therapeutic intervention for many different diseases, from rheumatoid arthritis and multiple sclerosis to inflammatory bowel disease and cancer
  • Consist of proteins and monoclonal antibodies that can have many targets, making them an invaluable addition to the treatment of diseases
  • Over the last few years, they have expanded exponentially both in range and functionality, and their development continues to grow. 

Major limitations of biopharmaceuticals

  • Besides the huge benefits that come with the use of biologics, there is one major limitation that arises when using these therapeutics: anti-drug antibodies (ADAs)
  • Due to the fact that biologics are proteins, they can be recognised by the immune system as foreign molecules, and so the body can mount an immune response against them in the form of ADAs
  • Some ADAs neutralise the biologic drugs and decrease the drugs efficacy and increase its clearance, resulting in patient secondary unresponsiveness

Lack of clinical routine assessment

  • Despite our knowledge of ADA and low serum drug levels, these are not assessed routinely at a clinical level
  • This can be due to clinicians being unaware that there are tests that look at these, and a lack of knowledge on where these tests can be performed
  • The main aim of this website is to compile together a list of labs located in different European countries, that test for ADAs and drug levels for different biologics, in order for clinicians to be able to  order tests and assess unresponsiveness in their patients